Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy
- PMID: 31582817
- DOI: 10.1038/s41571-019-0285-2
Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy
Comment on
-
Tumour lineage shapes BRCA-mediated phenotypes.Nature. 2019 Jul;571(7766):576-579. doi: 10.1038/s41586-019-1382-1. Epub 2019 Jul 10. Nature. 2019. PMID: 31292550 Free PMC article.
References
-
- Bryant, H. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913–917 (2005). - DOI
-
- Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917–921 (2005). - DOI
-
- Fong, P. C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123–134 (2009). - DOI
-
- Jonsson, P. et al. Tumour lineage shapes BRCA-mediated phenotypes. Nature 571, 576–579 (2019). - DOI
-
- Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011). - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources